Cover: Re: Improving the Cost-Effectiveness of Colorectal Cancer Screening

Re: Improving the Cost-Effectiveness of Colorectal Cancer Screening

Published in: Journal of the National Cancer Institute, v. 92, no. 20, Correspondence, Oct. 18, 2000, p. 1691-1692

Posted on 2000

by Franka Loeve, Martin L. Brown, Rob Boer, John Dik F Habbema

The authors discuss sigmoidoscopy screening for colorectal cancer and net cost savings under expert-based assumptions. Costs and savings can also be calculated from the private perspective of a typical U.S. health maintenance organization (HMO), assuming that around 40% of the HMO participants aged 5075 years will no longer be enrolled within 10 years. The authors model also expects favorable health effects from sigmoidoscopy screening, and the decision to screen should be based on a favorable balance between health effects and the costs of screening rather than solely on a cost analysis.

This report is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.